Algorithms have been developed to guide the treatment of simple hypertension. The basic algorithms are modified in the face of concurrent medical conditions, taking into account the various pharmacological effects of antihypertensive agents. This article reviews the neuropsychiatric effects of the major classes of antihypertensive agents (ganglionic blockers, centrally acting agents, diuretics, vasodilators, beta-blockers, calcium channel blockers and angiotensin converting enzyme inhibitors). The purported efficacy of some antihypertensive agents in the treatment of psychiatric conditions is also discussed. Beneficial as well as adverse neuropsychiatric effects are reviewed. In this way, guidelines for the treatment of hypertension are suggested which take into account a broad spectrum of neuropsychiatric considerations.
KaplanN. M., Systemic Hypertension: Mechanisms and Diagnosis; Therapy, in Heart Disease: A Textbook of Cardiovascular Medicine, BraunwaldE. (ed.), W. B. Saunders and Co., Philadelphia, pp. 819–883, 1988.
2.
Veterans Administration Cooperative Study Group on Antihypertensive AgentsEffects of Treatment on Morbidity in Hypertension: II Results in Patients with Diastolic Blood Pressure averaging 90 through 114 mm Hg, Journal of the American Medical Association, 213: 1143–1152, 1970.
3.
Veterans Administration Cooperative Study Group on Antihypertensive AgentsEffects of Treatment on Morbidity in Hypertension: I Results in Patients with Diastolic Blood Pressure averaging 115 through 129 mm Hg, Journal of the American Medical Association, 202: 1028–1034, 1967.
4.
KannelW. B.DannenbergA. L., and AbbottR. D.Unrecognized Myocardial Infarction and Hypertension: The Framingham Study, American Heart Journal, 109: 581–585, 1985.
5.
Management CommitteeThe Australian Therapeutic Trial in Mild Hypertension, Lancet, 1: 1261–1267, 1980.
6.
Medical Research Council Working PartyMRC Trial of Treatment of Mild Hypertension: Principal Results, British Medical Journal, 291: 97–104, 1985.
7.
KaplanN. M.Therapy of Mild Hypertension: An Overview, American Journal of Cardiology, 53: 2A–8A, 1984.
8.
IPPPSH Collaborative GroupCardiovascular Risk and Risk Factors in a Randomized Trial of Treatment Based on the Beta-blocker Oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH), Journal of Hypertension, 3: 379–392, 1985.
9.
Hypertension Detection and Follow-Up Program Cooperative GroupFive-Year Findings of the Hypertension Detection and Follow-Up Program, I. Reduction in the Mortality of Persons with High Blood Pressure, Including Mild Hypertension, Journal of The American Medical Association, 242: 2562–2571, 1979.
10.
MacMahonS. W.CutlerJ. A.FurbergC. D.The Effects of Drug Treatment for Hypertension on Morbidity and Mortality from Cardiovascular Disease: A review of Randomized Controlled Trials, Progress in Cardiovascular Diseases, 39(supp 1): 99–118, 1986.
11.
MillerR. E.ShapiroA. P., and KingH. E.Effect of Antihypertensive Treatment on the Behavioral Consequences of Elevated Blood Pressure, Hypertension, 6: 202–208, 1984.
12.
RabkinJ. G.CharlesE., and KassF.Hypertension and DSM-III Depression in Psychiatric Outpatients, American Journal of Psychiatry, 140: 1072–1074, 1983.
13.
PaykelE. S.FlemingerR., and WatsonJ. P.Psychiatric Side Effects of Antihypertensive Drugs Other than Reserpine, Journal of Clinical Psychopharmacology, 2: 14–39, 1982.
14.
LemieuxG.DavignonA., and GenestJ.Depressive States during Rauwolfia Therapy for Arterial Hypertension: A Report of 30 Cases, Canadian Medical Association journal, 74: 522–526, 1956.
15.
PottashA. L. C.BlackH. R., and GoldM. R.Psychiatric Complications of Antihypertensive Medications, Journal of Nervous and Mental Disease, 169: 430–438, 1981.
16.
StouteJ. A. and HallW. D.Treatment of Essential Hypertension in the Psychiatric Patient, Emory University Journal of Medicine, 4: 19–24, 1990.
17.
FreisE. D., Mental Depression in Hypertensive Patients Treated for Long Periods with Large Doses of Reserpine, New England Journal of Medicine, 251: 1006–1008, 1954.
18.
KassI. and BrownE. C.Treatment of Hypertensive Patients with Rauwolfia Compounds and Reserpine, Journal of the American Medical Association, 159: 1513–1516, 1955.
19.
SmithW. H.ThurmR. H., and BromerL.Comparative Evaluation of Rauwolfia Whole Root and Reserpine, Clinical Pharmacology and Therapeutics, 10: 338–343, 1969.
20.
AydF. J.Drug-induced Depression—Fact or Fallacy, New York State Journal of Medicine, 58: 354–356, 1958.
21.
FlahertyJ. A.Psychiatric Complications of Medical Drugs, Journal of Family Practice, 9: 243–251, 1979.
22.
SolomonS.HotchkissE.SaravayS. M.Impairment of Memory Function by Antihypertensive Medication, Archives of General Psychiatry, 40: 1109–1112, 1983.
23.
DeMuthG. W. and AckermanS. H.Alpha-Methyldopa and Depression: A Clinical Study and Review of the Literature, American Journal of Psychiatry, 140: 543–538, 1983.
24.
PaykelE. S.Hallucinosis in Combined Methyldopa and Pargyline, British Medical Journal, 1: 803, 1966.
25.
JohnsonJ. M.Psychiatric Uses of Antiadrenergic and Adrenergic Blocking Drugs, Journal of Nervous and Mental Disease, 172: 123–132, 1984.
26.
ErenbergG.Pharmacologic Therapy of Tics in Childhood, Psychiatric Annals, 18: 399–408, 1988.
27.
JenikeM. A.Approaches to the Patient with Treatment-Refractory Obsessive Compulsive Disorder, Journal of Clinical Psychiatry, 51(suppl): 15–21, 1990.
28.
GianniniD. J.PascarziG. A.LoiselleR. H.Comparison of Clonidine and Lithium in the Treatment of Mania, American Journal of Psychiatry, 143: 1608–1609, 1986.
29.
HardyM. C.LecrubierV., and WidlocherD.Efficacy of Clonidine in 24 Patients with Acute Mania, American Journal of Psychiatry, 143: 1450–1453, 1986.
30.
GoldM. S.RedmondD. E., and KleberH. D., Clonidine Blocks Acute Opiate Withdrawal Symptoms, Lancet, II: 599–602, 1978.
31.
KuharM. J.Receptors for Clonidine in Brain: Insights into Therapeutic Actions, Journal of Clinical Psychiatry, 43: 17–19, 1982.
32.
LaCroixA. Z.WienpahlJ.WhiteL. R.Thiazide Diuretic Agents and the Incidence of Hip Fracture, New England Journal of Medicine, 322: 286–290, 1990.
33.
WeinbergerM. H.Antihypertensive Therapy and Lipids, Archives of Internal Medicine, 145: 1102–1105, 1985.
34.
LewisW. H.Iatrogenic Psychotic Depressive Reaction in Hypertensive Patients, American Journal of Psychiatry, 127: 1416–1417, 1971.
35.
RuddP. and BlaschkeT. F., Antihyptertensive Agents and the Drug Therapy of Hypertension, in The Pharmacological Basis of Therapeutics, GilmanA. G.GoodmanL. S.RallT. W., and MuradF. (eds.), Macmillan Publishing Co., New York, pp. 784–805, 1985.
36.
ShepherdA. M. M. and IrvineN. A.Differential Hemodynamic and Sympathoadrenal Effects of Sodium Nitroprusside and Hydralazine in Hypertensive Subjects, Journal of Cardiovascular Pharmacology, 8: 527–533, 1986.
37.
PerryH. M.Jr. and SchroederH. A.Syndrome Simulating Collagen Disease Caused by 1-hydrazinophthalazine (Apresoline), Journal of the American Medical Association, 154: 670–673, 1954.
38.
Physicians' Desk Reference, Medical Economics Co., 1990.
39.
GrahamR. M.ThorrellI. R.GairJ. M.Prazosin: The First Dose Phenomenon, British Medical Journal, 2: 1293–1294, 1976.
40.
BensonD.PetersonL. G., and BartayJ.Neuropsychiatric Manifestations of Antihypertensive Medications, Psychiatric Medicine, 1: 205–214, 1983.
41.
ConollyM. E.KerstingF., and DolleryC. T.The Clinical Pharmacology of Beta-adrenoceptor Blocking Drugs, Progress in Cardiovascular Disease, 19: 203–234, 1976.
42.
BenetL. Z. and SheinerL. W., Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination, in The Pharmacological Basis of Therapeutics, GilmanA. G.GoodmanL. S.RallT. W., and MuradF. (eds.), Macmillan Publishing Co., New York, pp. 3–34, 1985.
43.
La DuB. N.MandelH. G., and WayE. L. (eds.), Fundamentals of Drug Metabolism and Drug Disposition, Williams and Wilkens Publishing Co., Baltimore, 1971.
44.
DimsdaleJ. E.NewtonR. P., and JoistT.Neuropsychological Side Effects of Beta-Blockers, Archives of Internal Medicine, 149: 514–525, 1989.
45.
GengoF. M.FaganS. C.DePadovaA.The Effect of B-Blockers on Mental Performance in Older Hypertensive Patients, Archives of Internal Medicine, 148: 779–784, 1988.
46.
ChaddaK.GoldsteinS.ByingtonR.Effect of Propranolol after Acute Myocardial Infarction in Patients with Congestive Heart Failure, Circulation, 73: 503–510, 1986.
47.
BantW.Antihypertensive Drugs and Depression: A Reappraisal, Psychological Medicine, 8: 275–283, 1978.
48.
LaderM.B-Adrenoceptor Antagonists in Neuropsychiatry: An Update, Journal of Clinical Psychiatry, 49: 213–223, 1988.
49.
GreendykeR. M.KanterD. R.SchusterD. B.Propranolol Treatment of Assaultive Patients with Organic Brain Disease: A Double-Blind Crossover Placebo-Controlled Study, Journal of Nervous and Mental Disease, 174: 290–294, 1986.
50.
RateyJ. J.MorrillR., and OxenkrugG.Use of Propranolol for Provoked and Unprovoked Episodes of Rage, American Journal of Psychiatry, 140: 1356–1357, 1983.
51.
WilliamsD. T.MehlR.YudofskyS.The Effect of Propranolol on Uncontrolled Rage Outbursts in Children and Adolescents with Organic Brain Dysfunction, Journal of the American Academy of Child Psychiatry, 21: 129–135, 1982.
52.
LipinskiJ. F.ZubenkoG. S.BarrieraP.Propranolol in the Treatment of Neuroleptic-Induced Akathisia, Lancet, 2: 685–686, 1983.
53.
PittsF. N. and AllenR. E., Beta-Adrenergic Blockade in the Treatment of Anxiety, in The Biology of Anxiety, MathewR. J. (ed.), Brunner/Mazel, New York, pp. 134–161, 1982.
54.
PeetM.BethellM. S.CoatesA.Propranolol in Schizophrenia: 1 Comparison of Propranolol, Chlorpromazine and Placebo, British Journal of Psychiatry, 139: 105–111, 1981.
55.
KrausM. L.GottliebL. D.HorowitzR. I.Randomized Clinical Trial of Atenolol in Patients with Alcohol Withdrawal, New England Journal of Medicine, 313: 905–909, 1985.
56.
SchwartzJ. B.KeefeD.KatesR. E.Acute and Chronic Pharmacodynamic Interaction of Verapamil and Digoxin in Atrial Fibrillation, Circulation, 65: 1163–1170, 1982.
KleinE. and UhdeT. W.Controlled Study of Verapamil for Treatment of Panic Disorder, American Journal of Psychiatry, 145: 4, 1988.
62.
GianniniA. J.HouserW. L.Jr.LoiselleR. H.Antimanic Effects of Verapamil, American Journal of Psychiatry, 141: 1602–1603, 1984.
63.
DubovskyS. L.FranksR. D.AllenS.Calcium Antagonists in Mania: A Double-Blind Study of Verapamil, Psychiatry Research, 18: 309–320, 1986.
64.
WalshT. L.LavensteinB.LicameleW. L.Calcium Antagonists in the Treatment of Tourette's Disorder, American Journal of Psychiatry, 143: 1467–1468, 1986.
65.
PriceW. A., and GianniniA. J.Verapamil in Acute Psychosis, Psychosomatics, 27: 797, 1986.
66.
PickarD.WolkowitzO. M.DoranA. R.Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients, Archives of General Psychiatry, 44: 113–118, 1987.
67.
GavrasH., and GavrasI., Angiotensin Converting Enzyme Inhibitors: Properties and Side Effects, Hypertension11(supp II): II-37–II-41, 1988.
68.
CroogS. H.LevineS.TestaM. A.The Effects of Antihypertensive Therapy on the Quality of Life, New England Journal of Medicine, 314: 1657–1664, 1986.
69.
CohenL. M.AndersonG.WhiteR. F.Enalapril and Hypertension, American Journal of Psychiatry, 141: 1012–1013, 1984.
70.
McMahonT.Bipolar Affective Symptoms Associated with Use of Captopril and Abrupt Withdrawal of Pargyline and Propranolol, American Journal of Psychiatry, 142: 759–760, 1985.
71.
OlajideD., and LaderM.Psychotropic Effects of Enalapril Maleate in Normal Volunteers, Psychopharmacology, 86: 374–376, 1985.
72.
ZubenkoG. S., and NixonR. A.Mood-Elevating Effects of Captopril in Depressed Patients, American Journal of Psychiatry, 141: 110–111, 1984.
73.
ZusmanR. M.Alternatives to Traditional Step-Care Therapy for Hypertension, Practical Cardiology, 17: 55–70, 1991.
74.
PollareT.LithellH., and BerneC. A.A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension, New England Journal of Medicine, 321: 868–873, 1989.
75.
PasternakR. C.BraunwaldS. E., and SobelB. E., Acute Myocardial Infarction, in Heart Disease: A Textbook of Cardiovascular Medicine, BraumwaldE. (ed.), W. B. Saunders and Co., Philadelphia, pp. 222–1313, 1988.
76.
RischS. C.GroomG. P., and JanowskyD. S.Interfaces of Psychophannacology and Cardiology—Part 1, Journal of Clinical Psychiatry, 42: 23–34, 1981.
SatelS. L., and NelsonJ. C.Stimulants in the Treatment of Depression: A Critical Overview, Journal of Clinical Psychiatry, 50: 241–249, 1989.
79.
HorowitzD.LovenbergW.EngelmanK.Monoamine Oxidase Inhibitors, Tyramine and Cheese, Journal of the American Medical Association, 188: 1108–1110, 1964.
80.
SwiftR. M., and BlackH. R.Essential Hypertension: Psychiatric Aspects and Use of Psychotropics, Psychosomatics, 25: 737–745, 1984.
81.
BaldessariniR. J., Drugs and the Treatment of Psychiatric Disorders, in The Pharmacological Basis of Therapeutics, GilmanA. G.GoodmanL. S.RallT. W., and MuradF. (eds.), Macmillan Publishing Co., New York, pp. 387–445, 1985.
82.
PopeH. G.KeckP. E., and McElroyS. L.Frequency and Presentation of Neuroleptic Malignant Syndrome in a Large Psychiatric Hospital, American Journal of Psychiatry, 143: 1227–1233, 1986.
